Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S. Fuchs, Francesco Di Costanzo, David H. Ilson et al.|The Lancet Oncology|2019Cited by 282
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysisAlessandro Rizzo, Mario Giuliano, Francesca Matilde Schipilliti et al.|ESMO Open|2023Cited by 31
266P Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysisFrancesca Matilde Schipilliti, Mario Giuliano, Francesco Di Costanzo et al.|Annals of Oncology|2023Cited by 0